Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
CI · NYSE · Health Care Services
Cigna (CI) · oqro.io/stocks/CI · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$270.90−2.14 (−0.78%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
No open-market purchase by an insider of Cigna was filed in the last 90 days. The latest on record was on Nov 3, 2025.
Since 2019, Cigna insiders reported 9 open-market purchases and 220 sales on Forms 4 and 5, with purchases in 4 different years, most recently 2025.
In the last 90 days, 1 insider of Cigna (CI) reported 1 open-market sale worth $175K in total on SEC Form 4. The largest seller by value was Everett Neville, with $175K. Many insider sales follow a plan set in advance or cover taxes on stock awards; the filing says what was sold, not the reason.
Yes. Members of Congress disclosed 14 trades in Cigna (CI) in the last 12 months, each reported as a value range on a periodic transaction report. The most recent are from Rep. Julie Johnson (TX32), Sen. Alan Armstrong, Rep. Jared Moskowitz (FL23) and 2 other members.
Cigna's next results are expected on Feb 3, 2027, after the market closes. The date can move until the company confirms it. Insiders often trade in the weeks right after results.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
+0.5% (+$1.30) from Nov 20, 2025 to Nov 20, 2026 · adjusted daily closes
Adjusted close went from $269.60 on Nov 20, 2025 to $270.90 on Nov 20, 2026 (+0.5%). Disclosed in this range: 1 insider trade, 18 pre-arranged insider sales, 7 Congress trades, and 79 13F position changes for 4 quarters ending in it.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Health Care Services company based in Bloomfield, Connecticut.
Last 12 months
+0.5%
Market value
$71.4B
S&P 500 +5.7% over the same dates. Prices adjusted for splits and dividends.
Short interest: 6.23M shares sold short (2.4% of shares outstanding), −7.8% vs the previous count, 4.2 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Revenue, fiscal 2025
$275B
+11.2% vs the year before
Net income, fiscal 2025
$5.96B
As reported in the annual filing
Shares outstanding
264M
As of Oct 30, 2026
In fiscal 2025 the company spent $3.62B buying back its own shares and $1.61B on dividends. Cash actually paid, from its cash-flow statement.
Next ex-dividend date Dec 3, 2026: $1.56 a share (quarterly), payable Dec 17, 2026. Calendar
Fund moves
From a 13F filed Nov 16, 2026 covering holdings at Sep 30, 2026 — a quarter-end snapshot, not a live trade.
Neville Everett (Officer) plans to sell ~$175K of Cigna
Planned, from payFund moves
9 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Revenue
$73.7B
+5.6% vs the same quarter a year earlier
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
$25B
Debt $31.1B, cash $6.19B, at Sep 30, 2026
Net income, last 12 months
$5.99B
Operating profit covers interest 7.12x
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 5, 2026.
Revenue and earnings history, 10 fiscal yearsRevenue breakdown: where the money goesCompared with its peersEarnings dates and the stock's moves
On the public record for Cigna over the 12 months to Nov 22, 2026: 8 executive contributions (5th most among listed companies).
Recent moves
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Insiders of Cigna reported 9 open-market purchases and 220 sales since 2019; purchases in 4 different years, most recently 2025.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $66.8M19×19 trades |
| 2025 | $1M1×1 trade | $23.8M6×6 trades |
| 2024 | — | $74.3M36×36 trades |
| 2023 | — | $22.7M18×18 trades |
| 2022 | — | $69.8M39×39 trades |
| 2021 | $211K2×2 trades | $110M37×37 trades |
| 2020 | $1.19M2×2 trades | $111M47×47 trades |
| 2019 | $7.36M4×4 trades | $14M18×18 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Top officer leaving
“Cordani, who will retire as the CEO of the Company effective July 1, 2026.”
2 insiders sold ~$1.16M in the 60 days before
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Federal rules, proposed rules and notices that name the company by its legal name, from the Federal Register. Being named is not the same as being the target of a rule.
Against the S&P 500 over the year
Since Nov 19, 2025, CI is down 0.4% and the index fund is up 4.1%: 5 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much CI moves
Beta 0.1 (1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 251 trading days (1 = in step with it).
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
Congress
Funds and stakes
Contracts, lobbying and filings
Company reports, price and press
Who holds it
Attention
Things to keep in mind
People read Cigna's Wikipedia article about 150 times a day over the last week, close to the 150 on a usual day of the three months before.
May 16, 2026Busiest day: 250 views on May 19, 2026Nov 21, 2026
Views of the article The Cigna Group, by people (Wikimedia leaves out known bots). More readers means more attention, from news, results or anything else; it does not say anyone bought or sold. Source: Wikimedia pageviews.
The three months Jul 1, 2026 to Sep 30, 2026, compared with the same quarter a year earlier, from the quarterly report filed Nov 5, 2026. Quarterly reports are not audited. Read the filing
+5.6% on the same quarter a year earlier ($60.4B)
+6.1% on the same quarter a year earlier ($10.9B)
−21% on the same quarter a year earlier ($162M)
The segments reach the total once −$1.82B of items outside them is counted: corporate items, and the removal of sales between segments so they are not counted twice, as the company reports them.
Fiscal year Jan 1, 2025 to Dec 31, 2025, from the annual report filed Feb 26, 2026. Read the filing
+16% on the year before ($202B)
−11% on the year before ($53.1B)
−19% on the year before ($828M)
The segments reach the total once −$8.14B of items outside them is counted: corporate items, and the removal of sales between segments so they are not counted twice, as the company reports them.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 10,000 words.
The Cigna Group, together with its subsidiaries (either individually or collectively referred to as the "Company," "we," "us" or "our"), is a global health company committed to creating a better future for every individual and every community. Our subsidiaries offer a differentiated set of pharmacy, medical, behavioral, dental, and related products and services. For further information on our business and strategy, see Part I, Item 1 - "Business" of this Form 10-K.
And 26 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026 and Form 10-Q filed Nov 5, 2026. Revenue lines are the figures the company tags in its filing; OQRO shows a split only when its lines add up to the reported total revenue. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Last results
Nov 5, 2026
Within the 30 days after it, until Dec 5, 2026
Next results, expected
Feb 4, 2027
after the market closes; the date can move until the company confirms it
Purchases after results
Not enough history
From Cigna's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Cigna's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.
Latest annual report filed Feb 26, 2026, compared with the one filed Feb 27, 2025. Read the filing
The information contained under "Legal and Regulatory Matters" in Note 22 to the Consolidated Financial Statements of this Form 10-K is incorporated herein by reference.
The company describes its cases in the notes to its financial statements, in the same filing.
Source: SEC EDGAR, Form 10-K filed Feb 26, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Short sale volume: 44.6% of the volume reported to FINRA over the last 20 trading days was marked short, close to its 1-year average of 44.7%. FINRA daily files, to Nov 20, 2026.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock.
Off-exchange trading: 44.7% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (26.6% on ATS, 18.1% with other brokers), close to its 26-week average of 44.3%. Weeks of Oct 5 to Oct 30, 2026.
Largest ATS: INTELLIGENT CROSS LLC (12.5%), SIGMA X2 (11.8%), UBS ATS (11.5%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.